BioNTech RNA Pharmaceuticals GmbH
BioNTech is a global leader in immunotherapies, dedicated to developing innovative treatments for cancer, infectious diseases, and other serious conditions. Founded by scientists and physicians, the company leverages scientific precision, innovation, and passion to improve lives worldwide through its research, development, and manufacturing of vaccines and therapies. The company emphasizes cutting-edge research in immunology, mRNA technology, and personalized medicine, with a strong focus on global health initiatives, partnerships, and expanding manufacturing capabilities, including innovative modular mRNA production facilities like BioNTainer in Kigali, Rwanda.
Industries
Nr. of Employees
Very Large (1000+)
BioNTech RNA Pharmaceuticals GmbH
An der Goldgrube 12, 55131 Mainz, Germany
Patents
5′-cap-trinucleotide- or higher oligonucleotide compounds and their use in stabilizing RNA, expressing proteins in therapy
US-12281138-B2
View DetailsMethods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
US-12270813-B2
View Details
5′-cap-trinucleotide- or higher oligonucleotide compounds and their use in stabilizing RNA, expressing proteins in therapy
US-12281138-B2
View DetailsMethods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
US-12270813-B2
View DetailsProducts
Commercial mRNA prophylactic vaccines
mRNA-based prophylactic vaccines manufactured at commercial scale for prevention of infectious diseases.
Individualized neoantigen mRNA cancer vaccines
Personalized mRNA vaccine candidates that target patient-specific tumor neoantigens identified by sequencing for adjuvant and early-intervention oncology use.
Off-the-shelf mRNA cancer vaccine candidates
Non-personalized mRNA vaccine candidates designed for defined tumor types or shared antigens to enable broader patient applicability.
Engineered cell therapy candidates
Preclinical and clinical-stage engineered T‑cell therapy candidates for oncology indications using CAR‑T and TCR approaches.
Antibody therapeutics and bispecific immunomodulators
Monoclonal and bispecific antibody candidates addressing immune checkpoints and tumor microenvironment pathways.
Antibody–drug conjugate (ADC) candidates
ADC product candidates combining targeted antibodies with cytotoxic payloads for oncology indications.
Commercial mRNA prophylactic vaccines
mRNA-based prophylactic vaccines manufactured at commercial scale for prevention of infectious diseases.
Individualized neoantigen mRNA cancer vaccines
Personalized mRNA vaccine candidates that target patient-specific tumor neoantigens identified by sequencing for adjuvant and early-intervention oncology use.
Off-the-shelf mRNA cancer vaccine candidates
Non-personalized mRNA vaccine candidates designed for defined tumor types or shared antigens to enable broader patient applicability.
Engineered cell therapy candidates
Preclinical and clinical-stage engineered T‑cell therapy candidates for oncology indications using CAR‑T and TCR approaches.
Antibody therapeutics and bispecific immunomodulators
Monoclonal and bispecific antibody candidates addressing immune checkpoints and tumor microenvironment pathways.
Antibody–drug conjugate (ADC) candidates
ADC product candidates combining targeted antibodies with cytotoxic payloads for oncology indications.
Services
Clinical and commercial GMP manufacturing services for RNA-based vaccines and other biologics, including process development, scale-up, quality control and batch release.
Provision, installation and technology transfer for turnkey modular manufacturing units configured as ISO-standardized container cleanrooms for localized production and formulation.
Partnered research programs and licensing arrangements to co-develop vaccines, immunotherapies and enabling technologies with academic and industry collaborators.
Support for clinical trial design, regulatory interactions, trial management and late-phase study execution with integrated safety and pharmacovigilance capabilities.
Development of global regulatory strategies, CMC planning and regulatory interactions to support marketing authorization and product labeling.
Clinical and commercial GMP manufacturing services for RNA-based vaccines and other biologics, including process development, scale-up, quality control and batch release.
Provision, installation and technology transfer for turnkey modular manufacturing units configured as ISO-standardized container cleanrooms for localized production and formulation.
Partnered research programs and licensing arrangements to co-develop vaccines, immunotherapies and enabling technologies with academic and industry collaborators.
Support for clinical trial design, regulatory interactions, trial management and late-phase study execution with integrated safety and pharmacovigilance capabilities.
Development of global regulatory strategies, CMC planning and regulatory interactions to support marketing authorization and product labeling.
Expertise Areas
- mRNA therapeutics and vaccine development
- Individualized neoantigen cancer vaccines
- Engineered cell therapies (CAR‑T, TCR)
- Antibody therapeutics and bispecific engineering
Key Technologies
- mRNA therapeutics
- In vitro transcription
- Plasmid DNA production
- Lipid nanoparticle (LNP) delivery
News & Updates
BioNTech's Mission and Vision
BioNTech aims to develop new immunotherapies based on scientific insights to improve lives globally.
Global Leadership in Immunotherapy
BioNTech is committed to advancing immunotherapies for cancer and infectious diseases, with a focus on innovative platforms like mRNA and cell therapies.
Partnerships and Collaborations
The company collaborates with leading pharma and biotech firms, universities, and organizations worldwide to accelerate medical breakthroughs.
Research & Development Milestones 2024
BioNTech has advanced its clinical portfolio and strengthened AI-driven research capabilities.
BioNTech's Approach to Immunotherapy
The company focuses on harnessing the immune system to fight cancer, infections, and other diseases through personalized and targeted therapies.
Innovative Technologies and Platforms
BioNTech's extensive experience in immunology and mRNA technology underpins its development of vaccines and therapies.
BioNTech's Mission and Vision
BioNTech aims to develop new immunotherapies based on scientific insights to improve lives globally.
Global Leadership in Immunotherapy
BioNTech is committed to advancing immunotherapies for cancer and infectious diseases, with a focus on innovative platforms like mRNA and cell therapies.
Partnerships and Collaborations
The company collaborates with leading pharma and biotech firms, universities, and organizations worldwide to accelerate medical breakthroughs.
Research & Development Milestones 2024
BioNTech has advanced its clinical portfolio and strengthened AI-driven research capabilities.
BioNTech's Approach to Immunotherapy
The company focuses on harnessing the immune system to fight cancer, infections, and other diseases through personalized and targeted therapies.
Innovative Technologies and Platforms
BioNTech's extensive experience in immunology and mRNA technology underpins its development of vaccines and therapies.